Clinical Trial Update: Long Term Safety Study of PRALUENT [Phase 4]

View source ↗

Summary

Phase 4 long-term safety study of PRALUENT has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heterozygous Familial Hypercholesterolemia
• Non-familial Hypercholesterolemia

Drugs mentioned

• Praluent (alirocumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Heterozygous Familial Hypercholesterolemia, Non-familial Hypercholesterolemia | Phase 4 | Status: TERMINATED | Results posted: 2021-06-15